New drugs and combinations for the treatment of soft-tissue sarcoma: a review

rugs and combinations for the treatment of soft-tissue sarcoma: a review Review (1763) Total Article Views Authors: Somaiah N, von Mehren M Published Date November 2012 Volume 2012:4 Pages 397 - 411 DOI: http://dx.doi.org/10.2147/CMAR.S23257 Received: 12 July 2012 Accepted: 27 September 2012 Published: 23 November 2012 Neeta Somaiah,1 Margaret von Mehren2 1Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA Abstract: Sarcomas are a heterogeneous group of solid tumors arising from either soft tissues or bone, accounting for approximately 1% of all cancers in adults. Management of these diseases has changed little over the past 10 years, with the exception of treatment of gastrointestinal stromal tumors. Reasons for this stagnation include multiple histologies commonly grouped together in clinical trials limiting the understanding of benefit of treatment and limited investigation of molecular targeted therapies. More recently, advances in molecular pathogenesis, the advent of novel and targeted therapeutics, and increasing collaborations between sarcoma investigators has helped move the field forward in the right direction. Here, we review the recent data on novel agents tested for the management of adult soft-tissue sarcomas, excluding gastrointestinal stromal tumors.